Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life.
Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life.
复制标题
DOI：
10.1007/s40471-021-00264-7
复制
发表时间：
2021-09
影响因子：
3.3
通讯作者：
McDermott CL
中科院分区：
文献类型：
--
作者：
Tjia J;Lund JL;Mack DS;Mbrah A;Yuan Y;Chen Q;Osundolire S;McDermott CL
To describe approaches to measuring deprescribing and associated outcomes in studies of patients approaching end of life (EOL). We reviewed studies published through 2020 that evaluated deprescribing in patients with limited life expectancy and approaching EOL. Deprescribing includes reducing the number of medications, decreasing medication dose(s), and eliminating potentially inappropriate medications. Tools such as STOPPFrail, OncPal, and the Unnecessary Drug Use Measure can facilitate deprescribing. Outcome measures vary and selection of measures should align with the operationalized deprescribing definition used by study investigators. EOL deprescribing considerations include medication appropriateness in the context of patient goals for care, expected benefit from medication given life expectancy, and heightened potential for medication-related harm as death nears. Additional data are needed on how EOL deprescribing impacts patient quality of life, caregiver burden, and out-of-pocket medication-related costs to patients and caregivers. Investigators should design deprescribing studies with this information in mind.
登录
查看更多内容
影响因子：
2.8
作者：
Grande G;Morin L;Vetrano DL;Fastbom J;Johnell K
通讯作者：
Johnell K
影响因子：
2.4
作者：
Baldoni, Andre de Oliveira;Ayres, Lorena Rocha;Leira Pereira, Leonardo Regis
通讯作者：
Leira Pereira, Leonardo Regis
影响因子：
6.7
作者：
Curtin, D.;O'Mahony, D.;Gallagher, P.
通讯作者：
Gallagher, P.
影响因子：
6.3
作者：
Frankenthal, Dvora;Israeli, Avi;Lerman, Yehuda
通讯作者：
Lerman, Yehuda
影响因子：
2.4
作者：
Ailabouni, Nagham;Mangin, Dee;Nishtala, Prasad S.
通讯作者：
Nishtala, Prasad S.